TABLE 2.
Baseline characteristics and pharmacodynamics (PD) parameters result of the patients with dabigatran.
| Dabigatran dose | Target range | Results |
| N | – | 183 |
| Dose (mg) | – | 110 |
| Gender (Male,%) | – | 59.6 |
| Age, years | – | 72.11 ± 9.86 |
| BMI, kg/m2 | – | 26.74 ± 16.93 |
| APTT-0 h, s | 26.9–37.6 | 36.47 ± 8.40 |
| APTT-peak, s | 26.9–37.6 | 47.89 ± 4.43 |
| APTT-trough, s | 26.9–37.6 | 39.08 ± 9.74 |
| PT-0 h, s | 10.1–12.6 | 15.58 ± 5.90 |
| PT-peak, s | 10.1–12.6 | 14.04 ± 3.50 |
| PT-trough, s | 10.1–12.6 | 13.79 ± 6.15 |
| HTI-0 h, ng/mL | – | 4.06 ± 2.92 |
| HTI-peak, ng/mL | – | 145.57 ± 50.16 |
| HTI-trough, ng/mL | – | 63.74 ± 27.95 |
| HGB, g/L | 110–160 | 133.95 ± 17.55 |
| PLT, 109/L | 100–300 | 206.55 ± 91.07 |
| MPV, fL | 7.50–11.5 | 11.61 ± 13.29 |
| TG, mmol/L | 0.56–1.70 | 1.32 ± 0.63 |
| TCHO, mmol/L | 3.40–5.20 | 5.98 ± 27.97 |
| LDL, mmol/L | 2.10–3.10 | 2.23 ± 0.81 |
| HDL, mmol/L | 1.00–1.55 | 1.12 ± 0.34 |
| FIB, g/L | 2.00–4.00 | 2.85 ± 0.73 |
| D-dimer, μg/L | <200 | 530.81 ± 57.55 |
| TT, s | 12.5–16.5 | 47.00 ± 61.87 |
| HbA1c, % | 4.00–6.00 | 6.27 ± 0.99 |
| T3, nmol/L | 1.80–2.90 | 1.54 ± 0.36 |
| T4, nmol/L | 66.0–181 | 101.33 ± 25.47 |
| CREA, umol/L | 53.0–115 | 83.49 ± 19.34 |
| GFR, mL/min | – | 73.03 ± 17.19 |
| ALT, IU/L | 7.00–50.0 | 23.05 ± 15.16 |
| AST, IU/L | 13.0–40.0 | 24.76 ± 21.48 |
| HAS-BLED | – | 2.16 ± 1.04 |
| CHA2DS2-VASc | – | 3.79 ± 1.70 |
BMI, body mass index; HTI, hemoclot thrombin inhibitor; APTT, activated partial thromboplastin; PT, prothrombin time; HGB, hemoglobin; PLT, platelet; MPV, mean platelet volume; TG, triglyceride; LDL, low density lipoprotein; HDL, high density lipoprotein; FIB, fibrinogen; TT, thrombin time; T3, triiodothyronine; T4, thyroid hormone; CREA, creatinine; GFR, glomerular filtration rate; ALT, alanine aminotransferase; AST, aspartate aminotransferase.